ATE378043T1 - Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten - Google Patents

Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten

Info

Publication number
ATE378043T1
ATE378043T1 AT00989636T AT00989636T ATE378043T1 AT E378043 T1 ATE378043 T1 AT E378043T1 AT 00989636 T AT00989636 T AT 00989636T AT 00989636 T AT00989636 T AT 00989636T AT E378043 T1 ATE378043 T1 AT E378043T1
Authority
AT
Austria
Prior art keywords
treatment
amyloidosis
aromatic compounds
alpha
polyhydroxylated aromatic
Prior art date
Application number
AT00989636T
Other languages
English (en)
Inventor
Gerardo Castillo
Paula Choi
Alan Snow
Original Assignee
Proteotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotech Inc filed Critical Proteotech Inc
Application granted granted Critical
Publication of ATE378043T1 publication Critical patent/ATE378043T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00989636T 1999-12-30 2000-12-28 Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten ATE378043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17395899P 1999-12-30 1999-12-30
US09/748,748 US20010047032A1 (en) 1999-12-30 2000-12-26 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

Publications (1)

Publication Number Publication Date
ATE378043T1 true ATE378043T1 (de) 2007-11-15

Family

ID=26869723

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00989636T ATE378043T1 (de) 1999-12-30 2000-12-28 Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten

Country Status (10)

Country Link
US (4) US20010047032A1 (de)
EP (1) EP1244435B9 (de)
JP (2) JP4370072B2 (de)
AT (1) ATE378043T1 (de)
AU (1) AU2612101A (de)
CA (2) CA2392709C (de)
DE (2) DE60037139D1 (de)
DK (1) DK1244435T5 (de)
ES (1) ES2295078T3 (de)
WO (1) WO2001049281A2 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
JP4633897B2 (ja) * 2000-08-17 2011-02-16 長瀬産業株式会社 神経突起伸長剤
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
CA2433754A1 (en) * 2001-01-03 2002-07-11 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
WO2003013442A2 (en) * 2001-03-15 2003-02-20 Proteotech. Inc. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
PL205635B1 (pl) * 2001-04-09 2010-05-31 Inst Farmaceutyczny Nowe pochodne genisteiny i zawierające je środki farmaceutyczne
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
JP2003252766A (ja) * 2002-02-28 2003-09-10 Sanei Gen Ffi Inc シアニジン３−グルコシドを有効成分とする抗肥満及び／又は抗糖尿病剤
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
US20050220753A1 (en) * 2002-03-22 2005-10-06 Beijing Jiankai Technology Co., Ltd Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them
US20030229136A1 (en) * 2002-04-18 2003-12-11 Nurulain Zaveri Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
SI1511710T1 (sl) * 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
AU2003279213B2 (en) * 2002-10-11 2008-12-18 Cognitive Clarity Inc. Isolation, purification and synthesis of procyanidin B2 and uses thereof
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
WO2004096240A1 (en) * 2003-05-02 2004-11-11 Medpalett Pharmaceuticals As Anthocyanins useful for the treatment of diabetes, cardiovascular disorders and to lower the risk of adverse effects of hormone replacement therapy
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2005000288A2 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
JP4917889B2 (ja) * 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
JP5044122B2 (ja) * 2003-10-24 2012-10-10 株式会社明治 後期糖化最終生成物形成の新規阻害剤及びアルドース還元酵素阻害剤
US8029815B2 (en) 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
CN100496470C (zh) * 2004-07-19 2009-06-10 中国科学院上海生命科学研究院 多酚及其氧化物的应用
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
DE112005001901T5 (de) * 2004-08-04 2007-07-12 Aspira Biosystems Inc., Incline Village Einfangen und entfernen von Biomolekülen aus Körperflüssigkeiten unter Verwendung von partiellen molekularen Abdrücken
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US9579298B2 (en) 2004-12-02 2017-02-28 Piotr Chomczynski Antioxidant dietary supplement compositions and methods for maintaining healthy skin
US20070122509A1 (en) * 2004-12-02 2007-05-31 Molecular Research Center, Inc. Antioxidant dietary supplement compositions and methods for maintaining healthy skin
KR100673595B1 (ko) 2005-03-07 2007-01-24 영남대학교 산학협력단 푸스틴을 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물
ATE452632T1 (de) * 2005-04-07 2010-01-15 Astrum Therapeutics Pty Ltd Verbindungen zur behandlung von amyloidose und verhinderung des tods von beta-zellen bei diabetes mellitus typ 2
WO2006124000A1 (en) * 2005-05-20 2006-11-23 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
RU2420513C2 (ru) * 2005-07-21 2011-06-10 Релайанс Лайф Сайенсиз Пвт Лтд Соединения для лечения заболеваний, опосредованных липазой
EP1921916A2 (de) * 2005-08-11 2008-05-21 The Scripps Research Institute Genistein-hemmung von transthyretin-amyloidose
US20100310587A1 (en) * 2005-08-29 2010-12-09 Academia Sinica Immunomodulatory compositions
EP1973928A2 (de) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Selbstzusammengebaute fmoc-ff-hydrogele
ES2277567B1 (es) * 2005-12-30 2008-06-01 Universidad Del Pais Vasco Compuestos con propiedades neuroprotectoras.
WO2007097940A2 (en) * 2006-02-13 2007-08-30 Trustees Of Boston University Reca inhibitors with antibiotic activity, compositions and methods of use
KR20080096705A (ko) 2006-04-07 2008-10-31 선 텐 피토테크 컴퍼니 리미티드 안트라세네디온 화합물
WO2007132784A1 (ja) * 2006-05-15 2007-11-22 Niigata University アントラキノン誘導体を有効成分として含有する抗精神病薬、認知異常の治療薬
CN101091706B (zh) * 2006-06-23 2011-05-04 和泓生物技术（上海）有限公司 多巴胺转运蛋白激动剂及其用途
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
WO2008005577A2 (en) * 2006-07-07 2008-01-10 University Of South Florida Compositions of polyphenols and methods of use
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
US20100234348A1 (en) * 2006-08-04 2010-09-16 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
US8802638B1 (en) * 2007-01-25 2014-08-12 University Of South Florida Flavonoid treatment of glycogen synthase kinase-based disease
US8778986B1 (en) * 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
EP2117306A4 (de) * 2007-02-14 2010-02-10 Mars Inc Neurogene verbindungen
CN101244074A (zh) * 2007-02-16 2008-08-20 首都医科大学宣武医院 淫羊藿黄酮及其有效成分在制备促进神经细胞增殖和分化作用药物中的用途
WO2008109517A1 (en) * 2007-03-02 2008-09-12 University Of South Florida Neurodegenerative disease treatment using jak/stat inhibition
ES2500053T3 (es) * 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
US9526707B2 (en) 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
WO2009059218A1 (en) * 2007-10-31 2009-05-07 Phytomedics, Inc. Berry preparations for treatment of diabetes and metabolic syndrome
GB0821994D0 (en) * 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
CN102348720A (zh) 2009-03-09 2012-02-08 雷蒙特亚特特拉维夫大学有限公司 预防和治疗神经退行性疾病的组合物和方法
US9072730B2 (en) * 2009-05-14 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
EP2544674B1 (de) 2010-03-08 2017-10-25 Sloan Kettering Institute For Cancer Research Cdc7 kinase hemmer und deren verwendung
CN101780098A (zh) * 2010-03-13 2010-07-21 青岛大学 迷迭香酸-杨梅黄酮药物配方及其在治疗帕金森病中的应用
KR20110111594A (ko) * 2010-04-05 2011-10-12 서울대학교산학협력단 알파-시뉴클레인 유래 곱슬 아밀로이드 섬유의 제조방법, 이를 이용한 하이드로젤의 제조 방법 및 그 이용 방법
KR101723635B1 (ko) * 2010-09-28 2017-04-05 서울대학교 산학협력단 전도성 바이오-나노 융합 사슬 및 이의 제조방법
SG10202008097VA (en) 2010-12-23 2020-09-29 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
US8865754B2 (en) * 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
JP2013053133A (ja) * 2011-08-10 2013-03-21 Taisho Pharmaceutical Co Ltd 認知機能障害の予防及び／または治療用組成物
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
KR101301253B1 (ko) * 2011-12-09 2013-08-28 한국원자력연구원 방사선을 이용한 크로메논 유도체의 제조방법
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
CN102743367A (zh) * 2012-05-31 2012-10-24 兰州理工大学 路路通鞣质单体的用途
CN102940712B (zh) * 2012-12-07 2014-03-19 辽宁大学 枳实在制备抗朊病毒药物中的应用
US9862746B2 (en) * 2013-02-15 2018-01-09 The Regents Of The University Of Michigan Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
EP2962687B1 (de) * 2013-04-02 2019-06-05 The Doshisha Tau-aggregationshemmer
BR102013022567B1 (pt) * 2013-09-03 2021-09-21 Uniao Brasileira De Educacão E Assistência Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
KR102554779B1 (ko) * 2014-12-23 2023-07-11 슬로안-케테링인스티튜트퍼캔서리서치 그라나티신 b의 다형체
CN104546825A (zh) * 2014-12-30 2015-04-29 上海中医药大学 高良姜素的医药用途
KR101636733B1 (ko) * 2015-02-24 2016-07-07 인제대학교 산학협력단 에키노크롬 a를 유효성분으로 함유하는 운동능력 증진용 건강식품 및 이를 이용한 운동능력 증진방법
KR101818084B1 (ko) * 2015-04-14 2018-01-15 대구가톨릭대학교산학협력단 석송강 추출물 또는 이로부터 분리된 화합물을 포함하는 알츠하이머병의 예방 또는 치료용 조성물-ⅱ
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
AU2016369642A1 (en) * 2015-12-17 2018-08-02 Massachusetts Institute Of Technology Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물
EP3592425A1 (de) 2017-03-08 2020-01-15 Amazentis SA Verfahren zur verbesserung der mitophagie in probanden
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
CN107349199A (zh) * 2017-07-18 2017-11-17 华北制药集团新药研究开发有限责任公司 榴菌素类化合物的医药用途
KR102098780B1 (ko) * 2017-09-27 2020-05-26 농업회사법인 대제한약 주식회사 블랙쵸크베리 추출물을 포함하는 뇌질환 예방 또는 치료용 약학 조성물
CN107823295A (zh) * 2017-11-28 2018-03-23 江西中医药大学 栀子花在制备改善睡眠障碍或改善记忆力减退或通便或提高免疫力药物或保健食品中应用
CN111971042B (zh) * 2018-04-13 2024-01-02 刘承铉 用于确认作为阿尔茨海默病的致病因子的颗粒蛋白、抑制颗粒蛋白的聚集和治疗阿尔茨海默病的组合物及方法
WO2020130172A1 (ko) * 2018-12-18 2020-06-25 박 제임스 씨. 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물
GB2596491B (en) * 2018-12-18 2022-06-29 Sang Hee Kim Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients
EP3920721A1 (de) * 2019-02-08 2021-12-15 Industrial Técnica Pecuaria S.A. Antioxidative zusammensetzung mit quercetagetin und gallussäure
CN110548023A (zh) * 2019-09-19 2019-12-10 天津科技大学 胭脂虫红酸在制备抑制β-淀粉样蛋白聚集中的用途
CN111096972B (zh) * 2020-02-25 2023-07-14 成都医学院 一种预防和/或治疗阿尔茨海默症的药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729563A (en) * 1970-12-08 1973-04-24 Ciba Geigy Corp Method of treating movement disorders
US3833732A (en) * 1973-05-24 1974-09-03 Miles Lab Method of treating inflammation utilizing alkyl esters of gallic acid
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
JP2587842B2 (ja) * 1987-12-09 1997-03-05 株式会社ニチレイ 神経疾患治療・予防剤
GB2264707A (en) * 1991-06-18 1993-09-08 Roger Michael Marchbanks Acridine derivatives for treating alzheimer's disease
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5464619A (en) * 1994-06-03 1995-11-07 The Procter & Gamble Company Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration and drinkability
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
WO1997016191A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Inhibition of amyloidosis by 9-acridinones
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
AU3640297A (en) * 1996-06-06 1998-01-05 University Of Washington Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
AU4236297A (en) * 1996-08-26 1998-03-19 University Of Washington Therapeutic and diagnostic applications of perlecan domain splice variants
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
EP0959682B1 (de) * 1996-10-08 2007-11-28 University of Washington Therapeutische anwendungen von laminin und von proteinfragmenten die von laminin abgeleitet sind
US6933280B2 (en) * 1996-10-08 2005-08-23 Gerardo Castillo Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
CA2219605C (en) * 1996-10-31 2002-02-05 Deepa Ashok Khambe Method of stimulating gastrointestinal motility with ellagic acid
US5746441A (en) * 1996-12-02 1998-05-05 Rockwell Heavy Vehicle Suspension Systems, Inc. Center beam suspension system
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
ATE262915T1 (de) * 1997-01-16 2004-04-15 Univ Florida Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln
US6929808B2 (en) * 2000-11-03 2005-08-16 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
US6264994B1 (en) * 1997-05-15 2001-07-24 University Of Washington Compositions for treating alzheimer's disease and other amyloidoses
EP1019044B1 (de) * 1997-05-15 2007-04-11 University of Washington Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
US6346280B1 (en) * 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
US20030017998A1 (en) * 1997-05-16 2003-01-23 Snow Alan D. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
ES2200366T3 (es) * 1997-08-28 2004-03-01 University Of Washington Composiciones de sacaridos para el tratamiento de la enfermedad de alzheimer y otras amiloidoisis.
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CA2323090C (en) * 1998-03-13 2009-08-04 University Of Washington In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
IL143299A0 (en) * 1998-12-01 2002-04-21 Novo Nordisk As Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

Also Published As

Publication number Publication date
DK1244435T3 (da) 2008-03-17
US20110065657A1 (en) 2011-03-17
AU2612101A (en) 2001-07-16
US20010047032A1 (en) 2001-11-29
JP5366473B2 (ja) 2013-12-11
ES2295078T3 (es) 2008-04-16
JP4370072B2 (ja) 2009-11-25
CA2392709A1 (en) 2001-07-12
WO2001049281A3 (en) 2002-05-10
US20070191330A1 (en) 2007-08-16
WO2001049281A2 (en) 2001-07-12
EP1244435B9 (de) 2009-05-06
DE60037139D1 (de) 2007-12-27
CA2392709C (en) 2010-03-23
DE60037139T4 (de) 2009-11-19
JP2003532634A (ja) 2003-11-05
US20040152760A1 (en) 2004-08-05
EP1244435B1 (de) 2007-11-14
EP1244435A2 (de) 2002-10-02
CA2686468C (en) 2014-01-28
CA2686468A1 (en) 2001-07-12
DK1244435T5 (da) 2009-08-31
DE60037139T2 (de) 2008-09-18
JP2009001589A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
ATE378043T1 (de) Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200200183A1 (ru) Композиция, содержащая трамадол и противосудорожное лекарственное средство
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
TW200504034A (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
TW200635903A (en) Therapeutic agents
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
GB0225475D0 (en) Therapeutic agents
TW200633986A (en) Therapeutic agents
TW200502221A (en) Novel lactams and uses thereof
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE453617T1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
TW200509933A (en) Therapeutic agents
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BG105710A (en) 5ht1 antagonists for antidepressant therapy
SE0002729D0 (sv) Novel compound form
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1244435

Country of ref document: EP